Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H11NO2.C4H10N2 |
Molecular Weight | 335.3996 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CNCCN1.OC(=O)C2=CC(=NC3=C2C=CC=C3)C4=CC=CC=C4
InChI
InChIKey=VGHQOUCHEAXCJT-UHFFFAOYSA-N
InChI=1S/C16H11NO2.C4H10N2/c18-16(19)13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14;1-2-6-4-3-5-1/h1-10H,(H,18,19);5-6H,1-4H2
Molecular Formula | C16H11NO2 |
Molecular Weight | 249.264 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H10N2 |
Molecular Weight | 86.1356 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.un.org/esa/coordination/CL12.pdf
Curator's Comment: Description was created based on several sources, including
http://www.un.org/esa/coordination/CL12.pdf
Cinchophen, phenylcinchoninic acid, seems to have been discovered in 1887 by Doebner and Gieseke and to have been introduced into medicine under the trade name of atophan in 1908 by Nicolaier and Dohrn. Since that time it has been used extensively for gout as well as for other forms of arthritis and for the relief of pain of all types. Use of Cinchophen in humans ceased in the 1930s due to the discovery that it can cause serious liver damage.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P12841 Gene ID: 314322.0 Gene Symbol: Fos Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8981440 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Atophan Approved UseIt has been used extensively for gout as well as for other forms of arthritis and for the relief of pain of all types. |
Doses
Dose | Population | Adverse events |
---|---|---|
485.9 mg 3 times / day multiple, oral Dose: 485.9 mg, 3 times / day Route: oral Route: multiple Dose: 485.9 mg, 3 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
Other AEs: Jaundice, Nausea... |
485.9 mg 1 times / day multiple, oral Dose: 485.9 mg, 1 times / day Route: oral Route: multiple Dose: 485.9 mg, 1 times / day Sources: |
unhealthy, 38 years n = 1 Health Status: unhealthy Condition: acute rheumatism Age Group: 38 years Sex: F Population Size: 1 Sources: |
Disc. AE: Jaundice... AEs leading to discontinuation/dose reduction: Jaundice (grade 5) Sources: |
300 mg 1 times / day multiple, oral (mean) Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 57 - 67 years n = 3 Health Status: unhealthy Condition: gout Age Group: 57 - 67 years Sex: F Population Size: 3 Sources: |
Disc. AE: Hepatitis... Other AEs: Hepatic failure... AEs leading to discontinuation/dose reduction: Hepatitis (acute, 2 patients) Other AEs:Hepatic failure (severe|grade 5, 1 patient) Sources: |
0.5 g 1 times / day multiple, oral Dose: 0.5 g, 1 times / day Route: oral Route: multiple Dose: 0.5 g, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Disc. AE: Hepatitis, Agranulocytosis... AEs leading to discontinuation/dose reduction: Hepatitis Sources: Agranulocytosis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 485.9 mg 3 times / day multiple, oral Dose: 485.9 mg, 3 times / day Route: oral Route: multiple Dose: 485.9 mg, 3 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
|
Jaundice | 485.9 mg 3 times / day multiple, oral Dose: 485.9 mg, 3 times / day Route: oral Route: multiple Dose: 485.9 mg, 3 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
|
Nausea | 485.9 mg 3 times / day multiple, oral Dose: 485.9 mg, 3 times / day Route: oral Route: multiple Dose: 485.9 mg, 3 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
|
Jaundice | grade 5 Disc. AE |
485.9 mg 1 times / day multiple, oral Dose: 485.9 mg, 1 times / day Route: oral Route: multiple Dose: 485.9 mg, 1 times / day Sources: |
unhealthy, 38 years n = 1 Health Status: unhealthy Condition: acute rheumatism Age Group: 38 years Sex: F Population Size: 1 Sources: |
Hepatitis | acute, 2 patients Disc. AE |
300 mg 1 times / day multiple, oral (mean) Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 57 - 67 years n = 3 Health Status: unhealthy Condition: gout Age Group: 57 - 67 years Sex: F Population Size: 3 Sources: |
Hepatic failure | severe|grade 5, 1 patient | 300 mg 1 times / day multiple, oral (mean) Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 57 - 67 years n = 3 Health Status: unhealthy Condition: gout Age Group: 57 - 67 years Sex: F Population Size: 3 Sources: |
Agranulocytosis | Disc. AE | 0.5 g 1 times / day multiple, oral Dose: 0.5 g, 1 times / day Route: oral Route: multiple Dose: 0.5 g, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Hepatitis | Disc. AE | 0.5 g 1 times / day multiple, oral Dose: 0.5 g, 1 times / day Route: oral Route: multiple Dose: 0.5 g, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
A series of quinoline analogues as potent inhibitors of C. albicans prolyl tRNA synthetase. | 2001 Feb 26 |
|
Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS. | 2008 Jul |
|
Poly[bis-(μ-hemihydrogen 2-phenyl-quinoline-4-carboxyl-ato-κN,O)silver(I)]. | 2009 Jan 23 |
|
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1679861
The mean dose was 300 mg/day for a mean duration of 3-4 months
Route of Administration:
Unknown
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13694701
Cinchophen (200 ug /ml) reduced the response of the isolated guinea-pig ileum to bradykinin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:47:06 GMT 2023
by
admin
on
Fri Dec 15 17:47:06 GMT 2023
|
Record UNII |
O65C9QHG6D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB01308MIG
Created by
admin on Fri Dec 15 17:47:06 GMT 2023 , Edited by admin on Fri Dec 15 17:47:06 GMT 2023
|
PRIMARY | |||
|
855165-13-8
Created by
admin on Fri Dec 15 17:47:06 GMT 2023 , Edited by admin on Fri Dec 15 17:47:06 GMT 2023
|
PRIMARY | |||
|
DTXSID40234726
Created by
admin on Fri Dec 15 17:47:06 GMT 2023 , Edited by admin on Fri Dec 15 17:47:06 GMT 2023
|
PRIMARY | |||
|
71300650
Created by
admin on Fri Dec 15 17:47:06 GMT 2023 , Edited by admin on Fri Dec 15 17:47:06 GMT 2023
|
PRIMARY | |||
|
100000084810
Created by
admin on Fri Dec 15 17:47:06 GMT 2023 , Edited by admin on Fri Dec 15 17:47:06 GMT 2023
|
PRIMARY | |||
|
O65C9QHG6D
Created by
admin on Fri Dec 15 17:47:06 GMT 2023 , Edited by admin on Fri Dec 15 17:47:06 GMT 2023
|
PRIMARY | |||
|
59672-15-0
Created by
admin on Fri Dec 15 17:47:06 GMT 2023 , Edited by admin on Fri Dec 15 17:47:06 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |